The United States Food and Drug Administration (FDA) has accepted Bayer's New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian. The regulatory submission covers the prevention of secondary stroke in adult patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The FDA previously granted Fast Track designation to asundexian for this indication in 2023. This regulatory milestone is supported by positive findings from the global pivotal Phase 3 OCEANIC-STROKE clinical trial, which was presented at the International Stroke Conference 2026 in New Orleans and published in The New England Journal of Medicine. If approved, asundexian would introduce a novel therapeutic mechanism to address the substantial residual risk of recurrent stroke in patients receiving guideline-based antiplatelet therapy. Phase 3 OCEANIC-STROKE Demonstrates 26 Percent Stroke Reduction The double-blind, randomized Phase 3 OCEANIC-STROKE trial evaluated the efficacy and safety of asundexian added to standard background antiplatelet therapy across 741 clinical sites worldwide. A total of 12,327 patients presenting with acute non-cardioembolic ischemic stroke or high-risk TIA were enrolled and randomized. Participants received either asundexian at a dose of 50 mg daily or a matched placebo, with 6,162 patients assigned to the asundexian arm and 6,165 patients assigned to the placebo arm. Both cohorts were monitored over a median follow-up period of 19 months.
OCEANIC-STROKE Shows 26 Percent Stroke Reduction
The trial successfully met its primary efficacy endpoint, defined as the time to the first occurrence of ischemic stroke. Patients receiving asundexian demonstrated a statistically significant reduction in ischemic stroke incidence compared to the placebo cohort, recording event rates of 6.2 percent versus 8.4 percent (cause-specific hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.65 to 0.84; P < .001). This result corresponds to a 26 percent relative risk reduction in recurrent ischemic stroke. Secondary endpoint analyses confirmed that asundexian also achieved a 26 percent reduction in the risk of stroke of any kind, including hemorrhagic stroke, as well as a lower incidence of the composite outcome of cardiovascular death, myocardial infarction, or stroke.
Safety assessments demonstrated a favorable profile for asundexian without an increase in bleeding complications. The trial's primary safety endpoint was the time to first occurrence of major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH). Major bleeding occurred in 1.9 percent of patients in the asundexian group compared with 1.7 percent in the placebo group (cause-specific HR, 1.1; 95% CI, 0.85 to 1.44). Furthermore, rates of minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage, and fatal bleeding were similar between the study arms. Overall adverse events were reported in 69.3 percent of asundexian-treated patients and 70.1 percent of placebo recipients, while serious adverse event rates were 19.2 percent and 19.5 percent, respectively. Decoupling Thrombosis from Hemostasis in Secondary Stroke Care Stroke remains the fifth leading cause of death in the United States, imposing an immense public health and socioeconomic burden. Epidemiological data indicate that approximately 795,000 individuals in the United States experience a stroke annually. Among these cases, approximately 87 percent are ischemic in origin, and 23 percent represent recurrent events. Despite contemporary medical interventions, approximately one in five stroke survivors will experience another stroke within five years. Current American Heart Association and American Stroke Association clinical guidelines endorse antiplatelet therapy for non-cardioembolic secondary prevention, as traditional anticoagulants carry an elevated risk of major hemorrhage that limits their clinical utility in this population.
Factor XIa has emerged as a promising therapeutic target because of its distinct physiological roles in coagulation. While conventional anticoagulants indiscriminately impair both hemostasis and thrombosis, Factor XIa plays only a minor role in normal physiological hemostatic plug formation following vascular injury. In contrast, it contributes significantly to pathological thrombus growth and vessel occlusion. By selectively inhibiting Factor XIa, asundexian aims to mitigate pathological clot expansion while preserving essential clotting capabilities, decoupling antithrombotic efficacy from the bleeding risks that have historically constrained stroke prevention. Regulatory Acceleration and Strategic Cardiovascular Pipeline Bayer leadership emphasized the clinical significance of the FDA's decision to grant Priority Review. Yesmean Wahdan, M.D., Senior Vice President of U.S. Medical Affairs at Bayer, stated: "Secondary stroke remains a serious and persistent challenge, and the FDA's Priority Review designation underscores the urgency of advancing potential new approaches in secondary stroke prevention. We are proud of this important milestone that builds on our long-standing commitment to innovation in anti-thrombotic therapies and look forward to collaborating with the FDA as we work to bring asundexian to patients in need."
Bayer Executives and Analysts on Asundexian Outlook
Dr. Ashkan Shoamanesh, co-principal investigator of the OCEANIC-STROKE trial, noted that the consistent reduction in secondary events across all stroke subtypes provides confidence in asundexian as a potential option for secondary prevention across a broad patient population. At earlier corporate briefings, Stefan Oelrich, head of Bayer's pharmaceuticals division, noted that Phase 3 trial design was informed by Phase 2 subgroup data showing a 36 percent risk reduction in recurrent symptomatic ischemic stroke and TIA.
Financial analysts at Guggenheim Securities previously estimated the secondary stroke prevention market opportunity at $3 billion to $4 billion. As a major cardiovascular healthcare company, Bayer reported fiscal 2025 global sales of 45.6 billion euros and research and development expenditures of 5.8 billion euros, supporting approximately 88,000 employees worldwide. Priority Review shortens the FDA evaluation timeline, with a regulatory decision anticipated later this year, potentially offering post-stroke patients a vital new safeguard against recurrence.
